Literature DB >> 16165001

Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002).

Yoichi Hirakata1, Junichi Matsuda, Yoshitsugu Miyazaki, Shimeru Kamihira, Sayoko Kawakami, Yukihisa Miyazawa, Yasuo Ono, Nobuhiko Nakazaki, Yasuyoshi Hirata, Matsuhisa Inoue, John D Turnidge, Jan M Bell, Ronald N Jones, Shigeru Kohno.   

Abstract

We examined the prevalence of extended-spectrum beta-lactamase (ESBL)-producing strains of Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli, Proteus mirabilis, Citrobacter koseri, and Salmonella spp. that were isolated as part of the SENTRY Asia-Pacific Surveillance Program between 1998 and 2002. During the study period, a total of 6,388 strains were gathered from 17 medical centers in 7 countries and examined for ESBL production and hyperproduction of K. oxytoca chromosomal K1 beta-lactamase enzyme. High rates of confirmed ESBL-producing isolates were found in K. pneumoniae strains from Singapore (35.6%), followed by those from mainland China (30.7%), South Africa (28.1%), and the Philippines (21.9%), whereas the rates were less than 10% in Japan and Australia. ESBL-producing E. coli strains were also prominent in mainland China (24.5%), Hong Kong (14.3%), and Singapore (11.3%). ESBL-producing K. oxytoca were common in the Philippines (38.5%), Singapore (33.3%), and China (30.0%). Hyperproduction of K. oxytoca chromosomal K1 beta-lactamase enzyme was common in Australia and Japan. P. mirabilis strains from Singapore produced ESBL (17.9%) despite the low prevalence (0-8.1%) in other countries. Few ESBL-producing C. koseri and Salmonella spp. strains were found in Japan, Singapore, Taiwan, and South Africa. Although there was variation among countries in substrate preference, ceftazidime was more likely to detect presumptive ESBL phenotype in K. pneumoniae and aztreonam more likely in E. coli, whereas ceftriaxone was the best substrate for the confirmation of ESBL production. ESBL-producing strains showed high levels of co-resistance to aminoglycosides, tetracycline, trimethoprim-sulfamethoxazole, and ciprofloxacin. Imipenem retained activity against all ESBL-producing strains. Organisms expressing ESBLs are widely distributed in the Asia-Pacific region, although prevalence rates vary significantly.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16165001     DOI: 10.1016/j.diagmicrobio.2005.04.004

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  37 in total

1.  Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART).

Authors:  Daryl J Hoban; Samuel K Bouchillon; Stephen P Hawser; Robert E Badal; Vincent J Labombardi; Joseph DiPersio
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Multicenter antimicrobial susceptibility survey of gram-negative bacteria isolated from patients with community-acquired infections in the People's Republic of China.

Authors:  Thomas K W Ling; Jianhui Xiong; Yunsong Yu; Ching Ching Lee; Huifen Ye; Peter M Hawkey
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 3.  Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Authors:  Christian G Giske; Dominique L Monnet; Otto Cars; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

4.  Analysis of bla(SHV) codon 238 and 240 allele mixtures using Sybr green high-resolution melting analysis.

Authors:  Patiyan Andersson; Tegan Harris; Steven Y C Tong; Philip M Giffard
Journal:  Antimicrob Agents Chemother       Date:  2009-04-06       Impact factor: 5.191

5.  How can we fight against antimicrobial- resistant bacteria in the World Health Organization Western Pacific Region?

Authors:  Yoshiaki Gu; Mitsuo Kaku
Journal:  Western Pac Surveill Response J       Date:  2012-07-30

6.  Changes in bacterial epidemiology and antibiotic resistance among veterans with spinal cord injury/disorder over the past 9 years.

Authors:  Margaret A Fitzpatrick; Katie J Suda; Nasia Safdar; Stephen P Burns; Makoto M Jones; Linda Poggensee; Swetha Ramanathan; Charlesnika T Evans
Journal:  J Spinal Cord Med       Date:  2017-02-15       Impact factor: 1.985

7.  Selection of SHV extended-spectrum-beta-lactamase-dependent cefotaxime and ceftazidime resistance in Klebsiella pneumoniae requires a plasmid-borne blaSHV gene.

Authors:  David S Hammond; Tegan Harris; Jan Bell; John Turnidge; Philip M Giffard
Journal:  Antimicrob Agents Chemother       Date:  2007-11-12       Impact factor: 5.191

Review 8.  The continuing challenge of ESBLs.

Authors:  Federico Perez; Andrea Endimiani; Kristine M Hujer; Robert A Bonomo
Journal:  Curr Opin Pharmacol       Date:  2007-09-17       Impact factor: 5.547

9.  ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.

Authors:  Andrea Endimiani; Kristine M Hujer; Andrea M Hujer; Eliana S Armstrong; Yuvraj Choudhary; James B Aggen; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-10       Impact factor: 5.191

10.  Bacterial resistance surveillance in China: a report from Mohnarin 2004-2005.

Authors:  Y H Xiao; J Wang; Y Li
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-19       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.